Post on 14-Dec-2015
Simon K. Cheng1, Kevin Stephenson2, Lynn Shi2, Kunal Chaudhary1, Anshu Jain1, David P. Horowitz1, Sherry X. Yan2, Tony Wang1,
Clifford Chao1, Tom K. Hei1
1New York Presbyterian Hospital / Columbia University Medical Center, 2Columbia University, New York, NY
Poster # 1139
– cancer patients are exposed to catecholamines under chronic stress conditions
– promotes cellular proliferation, tumor invasion, angiogenesis, and resistance to chemotherapy-induced apoptosis
– beta-blockers commonly used to treat hypertension and cardiac disease
No BB BBTotal patients
(n=101)80% 20%
Age (avg) 64 yo 68 yo
Males 60% 71%
Stage IIIA N2+
75%73%
78%66%
HistologySquamous
AdenoCarcinoma NOS
26%57%16%
36%52%10%
– β-adrenergic pathway may regulate multiple processes that contribute to tumor progression and treatment response
– propranolol radiosensitizes lung cancer cells to radiation in vitro
– beta-blocker use was associated with a decreased distant metastases rate and improved overall survival at 1 year In LA-NSCLC pts treated with tri-modality therapy
– Need additional studies evaluating the benefits of beta-blocker use on radiation treatment response and lung cancer recurrence
– Commonly targeted medical pathways may have significant pleomorphic effects on the efficacy of cancer therapies
– e.g. NRG LU001
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC